Last update 14 Jun 2025

Oxymetazoline/ Pilocarpine (Allergan)

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
Oxymetazoline/ Pilocarpine, AGN-199201/AGN-190584
Target
ACHE
Action
activators
Mechanism
AChE activators(Acetylcholinesterase activators)
Therapeutic Areas
Eye Diseases
Active Indication-
Inactive Indication
Presbyopia
Originator Organization
Allergan, Inc.
Active Organization-
Inactive Organization
Allergan UC
License Organization-
Drug Highest PhasePendingPhase 2
First Approval Date-
Regulation-
Login to view timeline

Structure/Sequence

Molecular FormulaC16H25ClN2O
InChIKeyBEEDODBODQVSIM-UHFFFAOYSA-N
CAS Registry2315-02-8
View All Structures (2)

Related

1
Clinical Trials associated with Oxymetazoline/ Pilocarpine (Allergan)
NCT02595528
/ CompletedPhase 2
A Phase 2, Multicenter, Double-masked, Randomized, Vehicle-Controlled, Study of the Concurrent Use of AGN-190584 and AGN-199201 in Patients With Presbyopia
100 Clinical Results associated with Oxymetazoline/ Pilocarpine (Allergan)
Login to view more data
100 Translational Medicine associated with Oxymetazoline/ Pilocarpine (Allergan)
Login to view more data
100 Patents (Medical) associated with Oxymetazoline/ Pilocarpine (Allergan)
Login to view more data
100 Deals associated with Oxymetazoline/ Pilocarpine (Allergan)
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
PresbyopiaPhase 2
United States
Allergan UC
29 Apr 2016
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
NCT02595528 (CTgov)
Phase 2
Presbyopia
163
(AGN-190584 Vehicle)
aqdezvwdoo(gtxekfcryi) = hupzipycfl bnsiekbptx (uubfriowci, 0.48)
View more
-
22 Dec 2020
(AGN-190584 Lower Dose)
aqdezvwdoo(gtxekfcryi) = cwlckcqgdg bnsiekbptx (uubfriowci, 0.37)
View more
NCT02595528 | NCT02780115 (PA039, AAO2020)
Phase 2
Presbyopia
-
Pilocarpine 1.0%/Oxymetazoline 0.05%
oxabcugyha(vskebbxzor) = iftzclpqff cxgdlxiujg (pxllfvdewk )
Positive
13 Nov 2020
Pilocarpine 1.5%/Oxymetazoline 0.125%
oxabcugyha(vskebbxzor) = rgqlhnorus cxgdlxiujg (pxllfvdewk )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free